- Home
- PGEN vs ZLAB Comparison
PGEN vs ZLAB Comparison
Compare PGEN & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | ZLAB |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PGEN | ZLAB |
|---|---|---|
| Price | $3.34 | $19.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.67 | ★ $49.44 |
| AVG Volume (30 Days) | ★ 4.6M | 587.5K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | N/A | ★ N/A |
| Revenue | $230,981,000.00 | ★ $460,156,000.00 |
| Revenue This Year | $342.78 | $22.42 |
| Revenue Next Year | $478.46 | $29.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $1.11 | $15.96 |
| 52 Week High | $5.47 | $44.34 |
Technical Indicators
Market Signals| Indicator | PGEN | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 32.84 | 52.75 |
| Support Level | $2.99 | $16.65 |
| Resistance Level | $5.10 | $19.70 |
| Average True Range (ATR) | 0.33 | 0.72 |
| MACD | -0.13 | -0.09 |
| Stochastic Oscillator | 3.85 | 67.46 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.